NASDAQ · PHGE
Healthcare · Biotechnology
$0.15
Up+$0.01 (+3.94%)
Updated Sep 6, 2026, 12:06 PM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PHGE closed at $0.15 after 20 trading sessions, down 10.48% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $0.1417 | $0.1486 | $0.1371 | $0.1477 | 2.11M |
| Sep 3, 2026 | $0.139 | $0.1455 | $0.133 | $0.1421 | 2.5M |
| Sep 2, 2026 | $0.1435 | $0.145 | $0.13 | $0.1425 | 3.36M |
| Sep 1, 2026 | $0.1394 | $0.146 | $0.1316 | $0.143 | 4.29M |
| Aug 31, 2026 | $0.143 | $0.143 | $0.131 | $0.1371 | 2M |
| Aug 28, 2026 | $0.134 | $0.1495 | $0.1301 | $0.1384 | 3.48M |
| Aug 27, 2026 | $0.131 | $0.134 | $0.13 | $0.1322 | 369.34K |
| Aug 26, 2026 | $0.1336 | $0.1345 | $0.1303 | $0.131 | 920.67K |
| Aug 25, 2026 | $0.1357 | $0.1388 | $0.13 | $0.135 | 649.31K |
| Aug 24, 2026 | $0.1379 | $0.1379 | $0.1316 | $0.1341 | 588.25K |
| Aug 21, 2026 | $0.134 | $0.14 | $0.134 | $0.1375 | 966.36K |
| Aug 20, 2026 | $0.1382 | $0.14 | $0.137 | $0.1397 | 961.25K |
| Aug 19, 2026 | $0.134 | $0.1409 | $0.1325 | $0.1367 | 602.59K |
| Aug 18, 2026 | $0.1379 | $0.14 | $0.1356 | $0.136 | 372.12K |
| Aug 17, 2026 | $0.146 | $0.15 | $0.14 | $0.1445 | 740.88K |
| Aug 14, 2026 | $0.1595 | $0.1595 | $0.147 | $0.147 | 1.02M |
| Aug 13, 2026 | $0.1497 | $0.155 | $0.1451 | $0.1549 | 994.6K |
| Aug 12, 2026 | $0.16 | $0.16 | $0.1475 | $0.1483 | 761.54K |
| Aug 11, 2026 | $0.1608 | $0.1639 | $0.153 | $0.1588 | 670.59K |
| Aug 10, 2026 | $0.1678 | $0.172 | $0.15 | $0.165 | 2.42M |
The latest Smart Investors Daily articles mentioning PHGE.
PHGE research
Company profile and research snapshot.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 9, 2026 | HC Wainwright & Co. | Neutral | — |
| Nov 26, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 25, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 20, 2025 | HC Wainwright & Co. | Buy | — |
| May 16, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 4, 2026
BiomX Inc., to be renamed Tessera Defense and Homeland Security Inc. effective September 11, 2026 (NYSE:PHGE, HLSQ from September 11, 2026)) ("BiomX" or the "Company"), a company focused on defense,
Benzinga · Sep 1, 2026
BiomX Inc. (NYSE:PHGE) (the "Company") today announced that it will change its corporate name to Tessera Defense and Homeland Security Inc., effective at 12:01 a.m., Eastern Time, on September 11, 2026. The
Benzinga · Aug 31, 2026
U.S. stock futures were lower on Monday, as the Dow Jones, S&P 500 and Nasdaq 100 indices fell, following Friday's lower close.
Benzinga · Aug 31, 2026
US stock futures mixed, focus on SAIC, PHGE, PXS earnings; WMT settles opioid lawsuit; CANG expected to report loss. See premarket coverage.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PHGE.
